Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine, covering 2019-12-23 to 2019-12-23. Get the full timeline:
Most recent: Clinical Trial Update: Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer [Phase 1]